The S&P/ASX Small Ordinaries (ASX:XSO) closed at 3,500.90, down 0.38% or 13.40 points yesterday.
The small-cap benchmark has lost further ground over the past 5 trading days, declining 1.62% or 57.60 points over the period.
VivoPower PLC (NASDAQ:VIVO, FRA:51J) has fully retired the $28.8 million in shareholder debt it owed to AWN Holdings, eliminating the last of its principal obligation to the entity and sharpening its credit profile ahead of a planned AI data center buildout in Norway, according to a new analyst note from Noble Capital Markets.
Of the total, $16.5 million was converted under the company's second PIPE offering, while the remaining $12.3 million was repaid in cash.
Grey Matters Health (CSE:GREY, OTCQB:AGNPD, FRA:AGW0) announced that it has signed a professional services agreement with ProScan Reading Services to interpret brain PET scans from its planned NovaScan Neuroimaging Clinics location in Davie, Florida.
The clinic, which Grey Matters expects to open by September 30, will use ProScan’s fellowship-trained, board-certified subspecialty radiologists to interpret scans for patients being evaluated for Alzheimer’s disease and other neurological conditions, including frontotemporal dementia, Parkinson’s disease and Lewy body dementia. The scans will also be used for select neuro-oncology applications.
American Resources Corp (NASDAQ:AREC) said its minority holding ReElement Technologies Corporation has received a Minor Source air permit covering all planned production lines at its Marion, Indiana Supersite.
The permit clears one of the final non-commercial hurdles to commissioning the facility, which now shifts ReElement’s focus to equipment installation, commissioning and commercial production.
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP), the cancer immunotherapy developer, has won UK regulatory approval to run a late-stage trial of its lead drug in advanced melanoma.
The Medicines and Healthcare products Regulatory Agency (MHRA) has granted a clinical trial authorisation for the phase III registrational study of iSCIB1+.
ADX Energy Limited (ASX:ADX, OTC:ADXRF) has applied for two new exploration permits covering a combined 787 square kilometres in the Sicily Channel offshore Italy, potentially expanding its acreage around the company’s 100%-owned CR 150.AU permit.
The applications for the d 368 C.R.-AU and d 369 C.R.-AU permits cover 573.3 square kilometres and 213.7 square kilometres respectively and are directly adjacent to ADX’s existing acreage.
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has secured Australian Human Research Ethics Committee (HREC) approval for a further protocol amendment to its pivotal Phase 3 trial of RECCE® 327 Topical Gel (R327G), adding a 208-patient active-controlled study arm in diabetic foot infections (DFI).
The new randomised, non-inferiority arm will compare R327G directly with physician-selected antibiotics currently used to treat DFIs, generating comparative clinical data as Recce advances the treatment through its international regulatory program.
American Rare Earths Ltd (ASX:ARR, OTCQX:ARRNF) has appointed Nick Lissolo as chief commercial officer (CCO), expanding his responsibilities across the company’s Nasdaq listing plans, US investor relations, commercial partnerships and development of the Halleck Creek Rare Earths Project in Wyoming.
Lissolo, who joined American Rare Earths in March 2026 as vice president of corporate development and strategy, has been promoted to the senior executive team with immediate effect as the company moves Halleck Creek from evaluation toward development.